What is Genoskin?
Genoskin specializes in the development and provision of ready-to-use, high-tech human skin models. These models are designed to test chemical, pharmaceutical, and cosmetic products, generating reliable human data that serves as a crucial alternative to traditional animal experimentation. Founded in 2011 as a spin-off from the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse, Genoskin leverages real human tissue collected post-surgery. Their innovative technology maintains the viability and functionality of these skin samples in an ex vivo culture system, making them readily available for research and development.
How much funding has Genoskin raised?
Genoskin has raised a total of $8.7M across 1 funding round:
Other Financing Round
$8.7M
Other Financing Round (2025): $8.7M with participation from Occte and CAPTECH Santé Nutrition
Key Investors in Genoskin
Occte
Occte is a management company focused on developing strategic and sustainable sectors, particularly in Occitanie, France. They offer investment funds targeting energy transition and the real economy, aiming to combine sustainability with performance.
CAPTECH Santé Nutrition
CAPTECH Santé Nutrition is an investment fund dedicated to supporting early-stage biotechnology, health, and nutrition projects. They provide crucial connections to industrial and technology networks, backed by FINORPA Gestion.
What's next for Genoskin?
The recent major strategic investment signals a pivotal growth phase for Genoskin. This capital infusion is expected to accelerate the company's expansion into new markets and enhance its research and development capabilities. The focus will likely be on scaling production, further validating their technology with a broader range of industry partners, and solidifying their position as a leader in ethical and effective product testing solutions. Genoskin's trajectory suggests a strong emphasis on innovation and market penetration within the pharmaceutical, cosmetic, and chemical sectors.
See full Genoskin company page
